Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Sodium Chloride B7288: Identity and Evidence Scope
2026-10-12
Sodium chloride (NaCl), listed by APExBIO as SKU B7288, is an inorganic salt described for conceptual use in aqueous buffer preparation, ionic-strength control, osmotic balance, and selected cell culture media contexts. No matched research paper or product-specific outcome evidence was provided, so applicability and performance claims remain limited.
-
HNF4A-AS1 and Sorafenib Resistance in HCC
2026-10-12
This 2024 Theranostics study links reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through DECR1-associated lipid remodeling and weaker ferroptosis susceptibility. Its multi-model evidence is mechanistically suggestive but remains preclinical and does not establish a clinical biomarker or treatment.
-
1-Myristoylglycerophosphocholine: Evidence Boundaries
2026-10-11
A source-grounded overview distinguishing evidence for LysoPC-related fibrosis mechanisms from evidence specifically concerning 1-myristoylglycerophosphocholine (14:0 Lyso-PC).
-
Ciclesonide: Evidence, Uses, and Research Limits
2026-10-10
Ciclesonide is a glucocorticoid prodrug used in respiratory pharmacology research, with reported conversion to the more potent metabolite desisobutyryl-ciclesonide. This overview compares its asthma-related evidence with a separate 2026 study of desonide-based ERAD degraders and explains why the compounds should not be treated as interchangeable.
-
CREC Carbapenemase Genes: Transmission Evidence
2026-10-09
Chen et al. characterize carbapenemase-encoding genes, mobile genetic elements, resistance profiles, and strain relatedness in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong. The study links frequent plasmid-associated blaNDM-1 with multidrug resistance and substantial transfer potential, while also showing why molecular findings should not be equated automatically with documented hospital transmission.
-
Chlorambucil in Cancer Research: Evidence and Limits
2026-10-09
A source-grounded overview of Chlorambucil research, emphasizing nitrogen mustard biology, assay interpretation, conceptual applications, evidence quality, and limits on translating in vitro findings to clinical or cross-model conclusions.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-10-08
A 2024 bioRxiv preprint reports that three kinase inhibitors can do more than block p38α catalytic activity: they also increase WIP1-mediated dephosphorylation of the kinase activation loop. Biochemical and X-ray structural evidence supports a model in which inhibitor-stabilized activation-loop conformations expose the phospho-threonine, offering a mechanistic framework for designing more selective kinase-directed interventions.
-
Nystatin (Fungicidin): Evidence and Research Context
2026-10-08
Nystatin is a polyene antifungal whose research value centers on ergosterol-associated membrane disruption and activity against Candida species. This overview separates supplier-reported claims from peer-reviewed evidence, examines conceptual delivery applications, and defines the limits of extrapolating nanoparticle uptake findings to nystatin therapy.
-
Brefeldin A and Endothelial Stress Biology
2026-10-07
A source-grounded perspective on how Brefeldin A can help translational researchers connect ER-to-Golgi trafficking, ER stress, cancer-cell phenotypes, and endothelial injury biology—while keeping mechanistic claims separate from clinical evidence.
-
Ziprasidone Nanocrystals: Caco-2 Permeability Evidence
2026-10-07
Karaküçük and colleagues evaluated whether ziprasidone hydrochloride monohydrate nanocrystals could improve in vitro intestinal permeability relative to coarse drug powder. The study reported a 2.3-fold increase in Caco-2 permeability without a detectable reduction in cell viability, supporting nanocrystal formulation as a formulation-science strategy while leaving in vivo and clinical translation unresolved.
-
HCN4 Heat Sensing and Heart Rate Control
2026-10-06
A 2025 Nature Communications study identifies an M407/Y409 motif in the HCN4 S4–S5 linker as a critical determinant of heat-induced current and heart-rate acceleration. By combining computational modeling, channel mutagenesis, SAN-cell recordings, isolated-heart studies, and genetically modified mice, the authors connect thermal sensing with the established cAMP pathway that regulates cardiac pacemaking.
-
Localized BDNF Release in Early NMJ Assembly
2026-10-06
This study identifies podosome-like structures as spatial hubs for muscle-derived BDNF trafficking and release during the earliest stages of neuromuscular junction development. Using complementary cell-based, imaging, perturbation, and mouse genetic evidence, the authors link localized BDNF processing to the formation and subsequent nerve-dependent organization of acetylcholine receptor clusters.
-
EdU Imaging Kits (488): Evidence and Limits
2026-10-05
EdU fluorescence is a useful readout of DNA replication, but it is not synonymous with completed cell division or therapeutic response. This source-grounded overview explains the principle behind 5-ethynyl-2'-deoxyuridine detection, evaluates evidence from a recent non-small-cell lung cancer study of linarin, and defines the assay’s interpretive boundaries.
-
Deferasirox Fe3+ Chelate and Lysosomal Iron
2026-10-05
Deferasirox Fe3+ chelate is examined as a research lens for connecting ferric-iron handling with lysosomal stress, not as proof of a direct role in TCF25 biology. Grounded in a 2025 Cell Reports study, this article separates reported findings, testable research questions, and product-specific evidence limits.
-
Cy3 Goat Anti-Rabbit IgG (H+L): Product Overview
2026-10-03
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody, SKU K1209, is a Cy3-conjugated polyclonal secondary antibody described for detecting rabbit IgG in fluorescence-based immunoassays. No matched paper evidence is available for independent performance assessment.